Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group

Item

http://www.wikidata.org/entity/Q34484199

Q34484199

about

Advances in immunotherapy for melanoma Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis.Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Adjuvant treatment of melanoma Update on use of aldesleukin for treatment of high-risk metastatic melanoma.Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden.Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.Adjuvant therapy for high-risk melanoma Immunotherapy of melanoma: efficacy and mode of action.Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen displays differential nucleus-derived phenotypes.A long-term survivor with esophageal melanoma and pulmonary metastasis after single-stage esophagectomy and lobectomy: Case report and literature review.An unusual case of desmoplastic malignant melanoma.Second European post-chicago melanoma meeting 2012.Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.High frequency of brain metastases after adjuvant therapy for high-risk melanoma.Connexin 43 upregulation by dioscin inhibits melanoma progression via suppressing malignancy and inducing M1 polarization.Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.Adjuvant Therapy for Melanoma.Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies

P2860

Q26768558-9A609FC3-88D3-49A8-9090-0385135B8C37 Q36277934-24E5ABC6-44C9-4689-8C4F-7CED63A000D4 Q36346631-8D5C1039-4260-4D2B-B055-C630A6819526 Q36656595-AF829670-7910-466C-94BD-820B33A0561C Q37031696-CD633F49-7BFB-418E-B243-77B6A570989A Q37286731-E4B829BD-259D-445C-BCFD-93180BC4AF8A Q37687695-4BDB2444-D0BD-41ED-B279-5F65BDF365A4 Q37699156-10628D72-1B05-45D5-929A-3E2FC4E910FF Q38555842-E6432A0F-75EE-42EE-9FF9-E9017D795B02 Q38682131-44CD9564-9C4E-41CD-B3DC-B83EB460BDCB Q38886428-4B668E27-F2FD-4C55-8D5E-07D5A6EDD6B9 Q39326649-46AACC3D-19CA-4F04-8E8A-9F1223BBF098 Q39997210-17B6582C-4D0B-4A47-BE08-23FF346B880F Q42015329-6985D7FB-5FB8-4DD8-A01B-4917BFBBB525 Q44538901-734815FB-8C1B-4F20-9DE8-500C76D83DFA Q46020823-9DB19228-72A5-45CF-87CE-E7C9CCAC4319 Q46198099-B6121259-66D9-4EF1-B6EB-7FDAA2F9D561 Q46341637-AC70B73B-B2A7-4E9D-928B-DA5C8679199D Q46458615-1B136F29-E7DC-4283-8001-8CEF589EE4EC Q48177601-DD576571-A81E-467D-9474-5748BE44BAD1 Q49185022-35DB5DBB-8DCA-4787-8C82-3593DC1BF1D2 Q51052594-1112A677-B85F-48A6-94CB-3CFED9BA5E8E Q56896166-5E9A4FE0-9954-43B4-BE4C-C03710C0F4B7

P2860

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group

Item

http://www.wikidata.org/entity/Q34484199

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu